

SUSPECT ADVERSE REACTION REPORT

I. REACTION INFORMATION

1. PATIENT INITIALS (first, last) PRIVACY	1a. COUNTRY ISRAEL	2. DATE OF BIRTH			2a. AGE 15 Years	3. SEX Unk	3a. WEIGHT Unk	4-6 REACTION ONSET			8-12 CHECK ALL APPROPRIATE TO ADVERSE REACTION ☐ PATIENT DIED ☐ INVOLVED OR PROLONGED INPATIENT HOSPITALISATION ☐ INVOLVED PERSISTENT OR SIGNIFICANT DISABILITY OR INCAPACITY ☒ LIFE THREATENING ☐ CONGENITAL ANOMALY ☒ OTHER: Medically Significant
		Day	Month	Year				Day	Month	Year	
7 + 13 DESCRIBE REACTION(S) (including relevant tests/lab data) Event Verbatim [PREFERRED TERM] (Related symptoms if any separated by commas) Other Serious Criteria: Medically Significant, Medically Significant Infusion reaction to infliximab [Infusion related reaction] eczema [Eczema] Cellulitis [Cellulitis] skin absces [Abscess] Nonspecific rash [Rash] elevated liver enzymes for Adalimumab + ustekinumab [Hepatic enzyme increased] COVID-19 infection [COVID-19] Clostridioides difficile infection [Clostridium difficile infection]											

(Continued on Additional Information Page)

II. SUSPECT DRUG(S) INFORMATION

14. SUSPECT DRUG(S) (include generic name) #1) Infliximab (INFLIXIMAB) Unknown {Lot # Unknown} #2) Adalimumab (ADALIMUMAB) Solution for injection {Lot # Unknown}		20. DID REACTION ABATE AFTER STOPPING DRUG? ☐ YES ☐ NO ☐ NA
15. DAILY DOSE(S) #1) Unknown #2) Unknown	16. ROUTE(S) OF ADMINISTRATION #1) Unknown #2) Unknown	
17. INDICATION(S) FOR USE #1) Pediatric IBD (Inflammatory bowel disease) #2) Pediatric IBD (Inflammatory bowel disease)		21. DID REACTION REAPPEAR AFTER REINTRODUCTION? ☐ YES ☐ NO ☐ NA
18. THERAPY DATES(from/to) #1) Unknown #2) Unknown	19. THERAPY DURATION #1) Unknown #2) Unknown	

III. CONCOMITANT DRUG(S) AND HISTORY

22. CONCOMITANT DRUG(S) AND DATES OF ADMINISTRATION (exclude those used to treat reaction)		
23. OTHER RELEVANT HISTORY. (e.g. diagnostics, allergies, pregnancy with last month of period, etc.) From/To Dates Type of History / Notes Description Unknown		

IV. MANUFACTURER INFORMATION

24a. NAME AND ADDRESS OF MANUFACTURER Celltrion Inc. 13-3 Songdo-dong, Yeonsu-gu, Incheon 406-840 KOREA, REPUBLIC OF		26. REMARKS Medically Confirmed: Yes
	24b. MFR CONTROL NO. 2023IL007996	25b. NAME AND ADDRESS OF REPORTER NAME AND ADDRESS WITHHELD.
24c. DATE RECEIVED BY MANUFACTURER 13-APR-2023	24d. REPORT SOURCE ☐ STUDY ☒ LITERATURE ☒ HEALTH PROFESSIONAL ☐ OTHER:	
DATE OF THIS REPORT 19-APR-2023	25a. REPORT TYPE ☒ INITIAL ☐ FOLLOWUP:	

19-Apr-2023 09:26

ADDITIONAL INFORMATION**7+13. DESCRIBE REACTION(S) continued**

influenza-like disease [Influenza like illness]
 mycoplasma upper respiratory tract infection [Upper respiratory tract infection]
 sinusitis [Sinusitis]
 headache [Headache]
 elevated liver enzymes from Infliximab + vedolizumab [Hepatic enzyme increased]
 External otitis [Ear infection]
 psoriasis [Psoriasis]
 urticaria [Urticaria]
 folliculitis [Folliculitis]
 fever [Pyrexia]
 impetigo [Impetigo]
 Rash [Rash]
 Mycoplasma infection [Mycoplasma infection]

Case Description: This initial serious literature report was received from a healthcare professional in Israel on 13 Apr 2023: Yerushalmy-Feler A, Olbjorn C, Kolho KL, Aloj, M, Musto F, Martin-de-Carpi J, et al. Dual Biologic or Small Molecule Therapy in Refractory Pediatric Inflammatory Bowel Disease (DOUBLE-PIBD): A Multicenter Study from the Pediatric IBD Porto Group of ESPGHAN. Inflammatory Bowel Diseases. 2023; XX; 1-8.

The aim of this study was to evaluate the effectiveness and safety of dual biologics or combination of biologics and JAK inhibitor therapy in a larger than previously reported cohort of pediatric patients with IBD.

This was a retrospective cohort study from 14 centers affiliated with the Pediatric IBD Interest and Porto groups of European to be significant in the univariate analysis. All analyses were performed in the intention-to-treat population.

This case refers to male and female patients with a median age of 15 who experienced Infusion reaction to infliximab, cellulitis, skin abscess, mycoplasma upper respiratory tract infection, clostridioides difficile infection, sinusitis, impetigo, external otitis, cellulitis, urticaria, nonspecific rash, elevated liver enzymes, COVID-19 infection, influenza-like disease, headache, psoriasis, folliculitis, and eczema following therapy with Infliximab and Adalimumab.

The patient received Infliximab and Adalimumab both at unspecified dose, frequency, and route for pediatric IBD on unspecified therapy dates. Batch/lot numbers was not reported.

Co-suspect drugs included Vedolizumab, Ustekinumab, Corticosteroids, 5-ASA, 6-MP, Azathioprine, Methotrexate, Tofacitinib; all at unspecified dose, frequency, and route for pediatric IBD on unspecified therapy dates. Batch/lot numbers was not reported.

On unspecified dates, the patient's experienced Infusion reaction to infliximab, cellulitis, skin abscess, mycoplasma upper respiratory tract infection (coded to mycoplasma infection and upper respiratory tract infection), clostridioides difficile infection, sinusitis, impetigo, external otitis, cellulitis, urticaria, nonspecific rash (serious and non-serious), elevated liver enzymes, COVID-19 infection, influenza-like disease, headache, psoriasis, folliculitis, and eczema. Corrective treatment for the events, action taken with Infliximab and Adalimumab, and outcome of the events was not reported.

The patients relevant medical history, past and concomitant medications were not reported.

The authors concluded that this study demonstrated that a combination of 2 biologics or a biologic with small molecule therapy may be effective in children with refractory IBD. The efficacy should be weighed against the risk of serious adverse events. The ideal selection of dual biologic regimens remains to be determined.

The reporter assessed the events Infusion reaction to infliximab, cellulitis, skin abscess, nonspecific rash, elevated liver enzymes, and eczema as serious (life threatening). Causality of events were not reported. Furthermore, medically significant was added as seriousness criteria for events cellulitis and Clostridium difficile infection as these were IME terms and COVID-19 as it is in ASL.

Case comment: For Infliximab: Causality of Infusion related reaction, Eczema, Cellulitis, Abscess, Rash, COVID-19, Clostridium difficile infection (listed, serious), Hepatic enzyme increased, Upper respiratory tract infection, Mycoplasma infection, Influenza like illness, Sinusitis, Headache, Psoriasis, Ear infection, Urticaria (listed, non-serious) is related due to temporal relationship between onset of event and reported therapy. Causality of Hepatic enzyme increased (listed, serious) Rash, Pyrexia, Impetigo, Folliculitis (listed, non-serious) is not related as event is attributed to Adalimumab use. For Adalimumab: Causality of Hepatic enzyme increased, COVID-19 (listed, serious), Influenza like illness (unlisted, non-serious), Rash, Headache, Pyrexia, Impetigo, Folliculitis, Psoriasis (listed, non-serious) is related due to temporal relationship between onset of event and reported therapy. Causality of Infusion related reaction (unlisted, serious), Eczema, Cellulitis, Abscess, Rash, Clostridium difficile infection (listed, serious), Hepatic enzyme increased, Upper respiratory tract infection, Mycoplasma infection, Sinusitis, Ear infection, Urticaria (listed, non-serious) is not related as event is attributed to Infliximab use. The concomitant use of vedolizumab and ustekinumab confounds the medical assessment.

ADDITIONAL INFORMATION**14-19. SUSPECT DRUG(S) continued**

14. SUSPECT DRUG(S) (include generic name)	15. DAILY DOSE(S); 16. ROUTE(S) OF ADMIN	17. INDICATION(S) FOR USE	18. THERAPY DATES (from/to); 19. THERAPY DURATION
#3) VEDOLIZUMAB (VEDOLIZUMAB) {Lot # Unknown}; Regimen #1	Unknown; Unknown	Pediatric IBD (Inflammatory bowel disease)	Unknown; Unknown
#4) USTEKINUMAB (USTEKINUMAB) {Lot # Unknown}; Regimen #1	Unknown; Unknown	Pediatric IBD (Inflammatory bowel disease)	Unknown; Unknown
#5) TOFACITINIB (TOFACITINIB) {Lot # Unknown}; Regimen #1	Unknown; Unknown	Pediatric IBD (Inflammatory bowel disease)	Unknown; Unknown
#6) CORTICOSTEROIDS {Lot # Unknown}; Regimen #1	Unknown; Unknown	Pediatric IBD (Inflammatory bowel disease)	Unknown; Unknown
#7) 5-ASA (5-ASA) {Lot # Unknown}; Regimen #1	Unknown; Unknown	Pediatric IBD (Inflammatory bowel disease)	Unknown; Unknown
#8) 6-MERCAPTOPURINE MONOHYDRATE (6-MERCAPTOPURINE MONOHYDRATE) {Lot # Unknown}; Regimen #1	Unknown; Unknown	Pediatric IBD (Inflammatory bowel disease)	Unknown; Unknown
#9) AZATHIOPRINE (AZATHIOPRINE) {Lot # Unknown}; Regimen #1	Unknown; Unknown	Pediatric IBD (Inflammatory bowel disease)	Unknown; Unknown
#10) METHOTREXATE (METHOTREXATE) {Lot # Unknown}; Regimen #1	Unknown; Unknown	Pediatric IBD (Inflammatory bowel disease)	Unknown; Unknown

24d. Report Source Literature

Journal: Inflammatory Bowel Diseases

Author: Yerushalmy-Feler A, Olbjorn C, Kolho KL, Aloï M, Musto F, Martin-de-Carpi J, et al.

Title: Dual Biologic or Small Molecule Therapy in Refractory Pediatric Inflammatory Bowel Disease (DOUBLE-PIBD): Multicenter Study from the Pediatric IBD Porto Group of ESPGHAN

Volume: XX Year: 2023 Pages: 1-8